-
Worg Pharmaceuticals Raises RMB 400 Million in Series B Funding
•
Worg Pharmaceuticals, a Hangzhou-based developer of novel allergic drugs, reportedly raised RMB 400 million (USD 57.3 million) in a Series B financing round. This follows an RMB 200 million (USD 28.65 million) Series A funding round in January last year. The latest round was backed by Junson Capital, Lapam Capital,…
-
Luye Life Sciences Partners with Uzbekistan to Establish Vaccine Center
•
China-based Luye Life Sciences Group has struck a partnership with the Ministry of Innovation and Development of the Republic of Uzbekistan. The collaboration, which leverages respective advantageous resources, will lead to the establishment of the Uzbekistan Innovative Vaccine Center in Tashkent, Uzbekistan. The partnership also marks a comprehensive collaboration on…
-
Celregen Licenses Regenerative Therapy CLS001 from Japan’s Cellusion
•
Hangzhou Celregen Therapeutics Ltd, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196), has revealed a licensing deal agreement with Japan-based Cellusion Inc., a specialist in regenerative medicines. Under the deal, Celregen has secured development, manufacturing, and commercialization rights to Cellusion’s lead regenerative therapy candidate CLS001 – a…
-
Transcenta’s First-in-Class Gremlin1 Antibody TST003 Receives FDA IND Clearance
•
China-based Transcenta Holding Limited (HKG: 6628) announced that its TST003, a first-in-class, high affinity humanized monoclonal antibody (mAb) targeting Gremlin1, has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA). This milestone allows Transcenta to proceed with clinical trials for this novel cancer treatment. Gremlin1…
-
Bide Pharmatech Set for IPO on Shanghai’s STAR Market
•
Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make an initial public offering (IPO) of 16 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR), raising an estimated RMB 43.44 million (USD 6.2 million). The move marks a significant milestone for the…
-
NMPA Releases 58th Batch of Reference Drugs for Generic Quality Consistency Evaluation
•
The National Medical Products Administration (NMPA) has released the 58th batch of reference drugs for generic quality consistency evaluation (GQCE) work. This batch includes a total of 41 new specifications, among which 13 are injectables. The release aims to further standardize the quality of generic drugs in the Chinese market,…
-
Alphamab/3DMed’s Envafolimab Gains FDA Fast-Track Status for Sarcoma Treatment
•
Alphamab Oncology (HKG: 9966) and 3D Medicines’ envafolimab (KN035) has obtained fast-track status from the US Food and Drug Administration (FDA) for the treatment of locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) that have progressed after chemotherapy. This designation is expected to accelerate the development…
-
Guangdong Launches Free HPV Vaccination Program for School-aged Girls
•
Guangdong province has rolled out a free HPV vaccination program this month, aimed at improving immunization rates among young girls. According to the “Work Plan for Free Human Papillomavirus (HPV) Vaccine Vaccination for School-aged Girls in Guangdong Province (2022-2024)” released in November last year, the program will provide free vaccines…
